The study showed that 1 in 100 patients in the study experienced
an ischemic stroke within 90 days of a retinal infarction.
Not exact matches
Intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) can improve outcomes for patients with
ischemic stroke treated
within 4 1/2 hours of the onset of symptoms.
Because of the importance of rapid treatment, national guidelines recommend that hospitals complete the evaluation of patients with acute
ischemic stroke and begin intravenous tPA therapy for eligible patients
within 60 minutes of hospital arrival.
The clot - busting drug tissue plasminogen activator (tPA) to treat
ischemic stroke, should be given
within 4.5 hours of symptom onset.
Expression and functional analyses of the gene strongly suggest that PDE4D plays an important role in atherosclerosis, most likely by influencing the proliferation and migration of smooth muscle cells
within arteries that is central to the biology of
ischemic stroke.
In an ongoing clinical trial funded by the U.S. National Institutes of Health, 3K3A - APC alone is being given to patients
within a few hours of
ischemic stroke (blocked blood flow to the brain), to determine if the protein can help protect against brain damage.
Most
strokes — about 85 % — occur when a clot or some other obstruction blocks blood flow to (or
within) the brain; these are known as
ischemic strokes.
A milder form of a
stroke called a Trans
Ischemic Attack or TIA is generally not as difficult to insure as the symptoms usually go away
within 24 - 48 hours.